Cannabis Extract Eases Autism Symptoms in Landmark Trial

Photo by Rene Terp via Pexels.

A randomized, placebo-controlled trial out of Australia just gave the cannabis-and-autism conversation something it's been missing: hard, statistically significant numbers. In a 120-child study, a full-spectrum cannabis extract called NTI164 outperformed placebo on core measures of autism severity, adaptive functioning, and social responsiveness. That's not a testimonial or a small pilot study with a handful of families reporting anecdotal improvement -- it's the kind of controlled data regulators actually pay attention to.

The trial comes from Neurotech International, an Australian biopharmaceutical company, and it's worth separating from the handful of other cannabis-autism research programs currently running in Brazil, the United States, and Israel. Each is testing a different formulation, dose, and patient population, and lumping them together in a headline does a disservice to what's actually a fairly nuanced, multi-country research effort. NTI164 specifically is on a pharmaceutical development track, not a wellness-industry one. It's moving through FDA-reviewed Phase III trials right now, which means it's not something you can walk into a dispensary or health food store and buy. This is a drug candidate, still years from a pharmacy shelf, going through the same regulatory gauntlet as any other prescription medication.

Inside the NTI164 Trial Results

Photo by CDC via Unsplash.

The study behind this news was designed the way you'd want a serious clinical trial to be designed: double-blind, randomized, placebo-controlled, with 120 children on the autism spectrum enrolled across the program. Neither families nor clinicians knew who was receiving NTI164 and who was getting placebo during the initial treatment window, which is what makes the results credible rather than anecdotal.

On the measures that matter most to clinicians, the NTI164 group pulled ahead of placebo by a statistically significant margin. That included clinician-rated overall clinical severity, adaptive functioning scores, social responsiveness, and affective symptoms -- the kind of composite picture researchers use to judge whether a treatment is actually changing a child's day-to-day functioning, not just moving a single number on a rating scale. Caregivers backed this up from their own vantage point, reporting improved family quality of life alongside the clinical measures, which matters because parent-reported outcomes often diverge from clinician assessments in pediatric psychiatry research.

What strengthens the case further is what happened next. Once the double-blind phase ended, the placebo group crossed over into open-label NTI164 treatment -- and they showed gains similar to what the original treatment group experienced. Meanwhile, the kids who'd been on NTI164 from the start didn't backslide; their improvements held. That combination -- a delayed group catching up once they got the real drug, and the original group maintaining its gains -- is exactly the pattern you'd hope to see if the effect is real rather than a placebo response or statistical noise. The trial is registered as NCT05626959 on ClinicalTrials.gov for anyone who wants to check the primary source data themselves.

Why a Full-Spectrum Extract, Not Just CBD

Photo by Dad Grass via Pexels.

One detail that separates NTI164 from most of the CBD-and-autism research floating around is that it isn't an isolate. Purified CBD -- the kind extracted and refined down to a single molecule -- has dominated a lot of pediatric cannabinoid research because it's easier to standardize and regulate. NTI164 goes a different route: it's a full-spectrum plant extract containing roughly 0.08% THC, alongside a broader retained profile of cannabinoids, terpenes, and other plant compounds that typically get stripped out during isolate production.

Neurotech's researchers are leaning into the entourage effect to explain why this matters -- the working theory that whole-plant compounds interact synergistically, producing a therapeutic effect greater than any single cannabinoid could achieve on its own. It's a theory with real traction in cannabis pharmacology circles, though it's still being worked out scientifically, and NTI164's trial results give it a genuine data point rather than just more speculation.

The trial's dosing structure was methodical rather than casual. Children received 20mg/kg/day of NTI164 during an 8-week double-blind period, after which the study moved into an 8-week open-label maintenance phase. That was followed by a 2-week washout period -- time for the drug to clear the system before further assessment -- and then an extension phase running as long as 52 weeks for children continuing in the program. That's a long runway for a pediatric trial, and it reflects an intent to capture not just short-term symptom relief but whether benefits hold up over close to a year of use. It's a notably more involved design than the single-arm or shorter isolated-CBD studies that have characterized a lot of earlier autism-cannabinoid research.

From Lab to Pharmacy: The Regulatory Road Ahead

Photo by Tima Miroshnichenko via Pexels.

Positive Phase II results are a milestone, not a finish line, and Neurotech is treating them that way. NTI164 has now advanced into Phase III, a program the company has branded the Beyond Harmony study. The FDA has cleared Neurotech's Investigational New Drug application, which is the regulatory green light needed to open a US-based pharmacokinetic study -- essentially testing how the drug behaves in the body across a broader population before larger efficacy trials proceed.

A separate, newer trial registered as NCT07257939 is now recruiting children with ASD Level II or III through Monash Health in Victoria, Australia. It's structured as a 1:1 randomized, placebo-controlled study with assessments taken at baseline and again at Week 16, adding another data point to the growing body of evidence around this specific formulation.

None of this comes cheap, and Neurotech has been transparent about the financing side. The company raised roughly $4.5 million through a placement of about 321.4 million shares priced at $0.014 each, funding meant to carry operations through topline Phase III data. That's a modest sum by pharmaceutical development standards, and it underscores how much runway is still needed before this could reach approval.

Worth repeating plainly: even with strong Phase II numbers, NTI164 still has to clear Phase III and win FDA approval before any doctor could actually prescribe it. And the CBD or full-spectrum products already sitting on dispensary and retail shelves are not this drug -- they're differently formulated, differently dosed, and their legal status for treating something like autism varies widely depending on your state or country. Check local law before assuming otherwise.

How This Fits Into Broader Autism-Cannabis Research

Photo by cottonbro studio via Pexels.

NTI164 isn't happening in isolation -- it's one thread in a wider pattern of cannabinoid-autism research that's picked up noticeably in the past couple of years. In 2024, Brazilian researchers ran a randomized controlled trial testing a CBD-rich extract in 60 children with autism, adding a South American data point to a field that's historically been dominated by North American and Israeli research. In 2026, a team at NYU ran a Phase-2 open-label trial looking at CBD specifically in higher-functioning autistic youth, a population that's often underrepresented in cannabinoid trials that skew toward more severe presentations.

Israel has arguably the longest track record here. Researchers at Shaare Zedek Medical Center, led by Prof. Adi Aran, have spent several years studying CBD and terpene-enriched oil formulations for autism symptoms, building a body of work that predates a lot of the current wave of interest.

It's tempting to read all of this as one unified research story, but the formulations, dosing protocols, and trial designs differ enough that results from one shouldn't be assumed to apply to another. A CBD isolate tested in Brazil isn't the same intervention as a 0.08%-THC full-spectrum extract tested in Australia, even if both get filed under cannabis and autism in a news feed. What the accumulation of these efforts does signal, clearly, is rising scientific seriousness about cannabinoid-based approaches to autism -- independent teams across three continents are now running controlled trials rather than relying on parent surveys or case reports. That said, it's worth being precise: no cannabinoid formulation for autism has FDA approval yet. This is a field generating real signal, not yet a field with an answer.

Strip away the headlines and what's left is a genuinely encouraging but still incomplete picture. The signal is real, and it's coming from multiple independent research groups rather than one company with an incentive to talk up its own data. But NTI164 specifically remains years and one more full trial phase away from becoming an approved, prescribable medicine. Phase II success stories in pharmaceutical development don't always survive Phase III -- that's true across every therapeutic category, not just cannabinoids, and autism trials carry their own added complexity given how heterogeneous the condition is from one child to the next.

If you're a parent looking at this news and wondering what it means for your own child, the honest answer is: talk to a physician, and check your state or country's specific laws before pursuing any cannabis-based option. There's no version of this trial's exact formulation, dose, or protocol available for purchase anywhere right now, and trying to approximate a pharmaceutical-grade extract with dispensary products isn't the same intervention that produced these results -- it could carry different risks and simply won't replicate what was tested.

The number worth watching going forward isn't this Phase II readout -- it's the Beyond Harmony Phase III data. That's the trial that will actually determine whether NTI164 has a real path to FDA approval, and until that data lands, everything else is a promising but preliminary chapter in a much longer story.